{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:02:20Z","timestamp":1771063340141,"version":"3.50.1"},"reference-count":48,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2019,3,21]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Clonal haematopoiesis (CH) is defined by the presence of acquired mutations and\/or cytogenetic abnormalities in haematopoietic cells. By definition, these premalignant clones do not meet criteria for haematopoietic neoplasms listed in the Revised Fourth Edition of the WHO classification. CH is fairly common in elderly individuals and is associated with higher risks for haematological cancers, in particular myelodysplastic syndrome and acute myeloid leukaemia (AML), as well as cardiovascular events. Similar small clones have also been detected during follow-up in patients with AML in morphological remission, in individuals with aplastic anaemia, and in pre-chemotherapy blood samples from patients with other types of cancers. In each of these contexts, the presence of mutations carries different clinical implications, and sometimes demonstrates unique genetic profiles. Emerging research suggests that the number and identity of mutations, the size of the mutant clones and various other factors, including age, immune status and history of exogenous drugs\/toxins, are important for disease biology and progression. This review focuses specifically on the subset of CH with gene mutations detected by sequencing, and includes discussions of nomenclature and molecular technologies that detect and quantify gene mutations.<\/jats:p>","DOI":"10.1136\/jclinpath-2019-205851","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T17:25:29Z","timestamp":1559669129000},"page":"453-459","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging patterns in clonal haematopoiesis"],"prefix":"10.1136","volume":"72","author":[{"given":"Jose-Mario","family":"Capo-Chichi","sequence":"first","affiliation":[{"name":"Department of Molecular Genetics, Toronto General Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Michaels","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemarie","family":"Tremblay-Le May","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagi","family":"Abelson","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada"},{"name":"Ontario Institute for Cancer Research, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Paul","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-0577","authenticated-orcid":false,"given":"Daniel","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"2025121220032281000_72.7.453.1","unstructured":"Swerdlow SH , Campo E , Harris NL , et al . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4t. WHO Press: Lyon:, 2017."},{"key":"2025121220032281000_72.7.453.2","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121220032281000_72.7.453.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409405"},{"key":"2025121220032281000_72.7.453.4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3733"},{"key":"2025121220032281000_72.7.453.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-746453"},{"key":"2025121220032281000_72.7.453.6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ijlh.12826","article-title":"How I investigate clonal cytogenetic abnormalities of undetermined significance","volume":"40","author":"Tang","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"2025121220032281000_72.7.453.7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V88.1.59.59","article-title":"Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age","volume":"88","author":"Busque","year":"1996","journal-title":"Blood"},{"key":"2025121220032281000_72.7.453.8","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2413"},{"key":"2025121220032281000_72.7.453.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013343"},{"key":"2025121220032281000_72.7.453.10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.336"},{"key":"2025121220032281000_72.7.453.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-518886"},{"key":"2025121220032281000_72.7.453.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689"},{"key":"2025121220032281000_72.7.453.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610543"},{"key":"2025121220032281000_72.7.453.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"2025121220032281000_72.7.453.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075290"},{"key":"2025121220032281000_72.7.453.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701719"},{"key":"2025121220032281000_72.7.453.17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag1381"},{"key":"2025121220032281000_72.7.453.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-631747"},{"key":"2025121220032281000_72.7.453.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-667063"},{"key":"2025121220032281000_72.7.453.20","doi-asserted-by":"crossref","unstructured":"Malcovati L , Gall\u00ec A , Travaglino E , et al . Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 2017;129.doi:10.1182\/blood-2017-01-763425","DOI":"10.1182\/blood-2017-01-763425"},{"key":"2025121220032281000_72.7.453.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-663237"},{"key":"2025121220032281000_72.7.453.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414799"},{"key":"2025121220032281000_72.7.453.23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025121220032281000_72.7.453.24","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121220032281000_72.7.453.25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025121220032281000_72.7.453.26","doi-asserted-by":"publisher","DOI":"10.1038\/nature13968"},{"key":"2025121220032281000_72.7.453.27","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"key":"2025121220032281000_72.7.453.28","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.112"},{"key":"2025121220032281000_72.7.453.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0321-x"},{"key":"2025121220032281000_72.7.453.30","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/leu.2015.17","article-title":"Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing","volume":"29","author":"Young","year":"2015","journal-title":"Leukemia"},{"key":"2025121220032281000_72.7.453.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2017.05.013"},{"key":"2025121220032281000_72.7.453.32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169136"},{"key":"2025121220032281000_72.7.453.33","unstructured":"Cantsilieris S , Stessman HA , Shendure J , et al . Genotyping. New York, NY: Springer, 2017."},{"key":"2025121220032281000_72.7.453.34","doi-asserted-by":"crossref","unstructured":"Young AL , Challen GA , Birmann BM , et al . Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun 2016;7.doi:10.1038\/ncomms12484","DOI":"10.1038\/ncomms12484"},{"key":"2025121220032281000_72.7.453.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507471"},{"key":"2025121220032281000_72.7.453.36","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1172\/JCI91964","article-title":"Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse","volume":"127","author":"Parkin","year":"2017","journal-title":"J Clin Invest"},{"key":"2025121220032281000_72.7.453.37","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00277-018-3451-1","article-title":"A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in pH negative MPNs","volume":"97","author":"Link-Lenczowska","year":"2018","journal-title":"Ann Hematol"},{"key":"2025121220032281000_72.7.453.38","doi-asserted-by":"crossref","unstructured":"Valent P , Kern W , Hoermann G , et al . Clonal hematopoiesis with oncogenic potential (CHOP): separation from CHIP and roads to AML. Int J Mol Sci 2019;20. doi:doi:10.3390\/ijms20030789. [Epub ahead of print: 12 Feb 2019].","DOI":"10.3390\/ijms20030789"},{"key":"2025121220032281000_72.7.453.39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41591-018-0114-7","article-title":"Predicting progression to AML","volume":"24","author":"Sellar","year":"2018","journal-title":"Nat Med"},{"key":"2025121220032281000_72.7.453.40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"2025121220032281000_72.7.453.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0081-z"},{"key":"2025121220032281000_72.7.453.42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121220032281000_72.7.453.43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MOH.0000000000000465","article-title":"Age-related clonal hematopoiesis: implications for hematopoietic stem cell transplantation","volume":"25","author":"Abelson","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"2025121220032281000_72.7.453.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3044"},{"key":"2025121220032281000_72.7.453.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840629"},{"key":"2025121220032281000_72.7.453.46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1201"},{"key":"2025121220032281000_72.7.453.47","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jamaoncol.2018.2297","article-title":"Prevalence of clonal hematopoiesis mutations in Tumor-Only clinical genomic profiling of solid tumors","volume":"4","author":"Ptashkin","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121220032281000_72.7.453.48","doi-asserted-by":"crossref","unstructured":"Riedlinger G , Hadigol M , Khiabanian H , et al . Association of Jak2-V617F mutations detected by solid tumor sequencing with coexistent myeloproliferative neoplasms. JAMA Oncol 2019. doi:doi:10.1001\/jamaoncol.2018.6286. [Epub ahead of print: 03 Jan 2019].","DOI":"10.1001\/jamaoncol.2018.6286"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-205851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:03:31Z","timestamp":1765598611000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-205851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,6,20]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/jclinpath-2019-205851"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-205851","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]}}}